Abstract
THE AIM.To evaluate the effect of the sodium-glucose cotransporter SGLT-2 inhibitor - empagliflozin on the kidney in nondiabetic Wistar rats with experimental heart failure (HF).MATERIAL AND METHODS. Cronic heart failure (CHF) was induced by ligation the left coronary artery. Animals with CHF in the first group (n=11) received empagliflozin (Jardiance®, Boehringer Ingelheim) orally (1 mg / kg/day) for 1 month. In the second group of rats with CHF (n = 10) the drug is not administered. Systolic blood pressure, heart rate, concentrations and daily urinary excretion of glucose, albumin, creatinine, urea and essential ions were measured. The relative level of microRNA-21 urinary expression was established.RESULTS.Empagliflozin administration led to an increase in glycosuria, albuminuria, and the expression of microRNA-21 in urine. However in this conditions inorganic phosphorus excretion decreased. Empagliflozin did not influence on blood pressure, heart rate or levels of investigated substances excretion including sodium.CONCLUSION. The findings suggest that the SGLT-2 inhibitors may have some negative direct effects on the kidneys. However, in diabetes, such effects of these drugs can be masked by powerful nephroprotective actions associated with the ability of SGLT-2 inhibitors to counteract hyperglycemia and glomerular hyperfiltration.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
